Panama Clears Five-Patient Knee Cartilage Implant Trial, Taking Chondrograft into Human Safety Testing

Once a localized defect forms in knee cartilage, the body has limited ability to repair it on its own, and patients may find themselves in a treatment gap where conservative care is insufficient but they are not yet suitable for total knee replacement. Panama’s health authority has now allowed Nanochon to begin an early feasibility study of Chondrograft, moving this implant, which combines structural support with a tissue-repair concept, into further human testing.

According to the ClinicalTrials.gov registration, the Panama study is identified as NCT07542184 and is expected to enroll five adults aged 22 to 60 with localized knee cartilage lesions. All participants will receive a Chondrograft implant, using either a mini-open arthrotomy or arthroscopy; the study has no control group and is not blinded. It will take place at The Panama Clinic in Panama City, with Dr. Juan Osorio serving as the principal investigator.

Chondrograft is a fully synthetic implant. Nanochon’s design concept is to first provide mechanical support at the damaged site and then serve as a scaffold for the growth of cells and new tissue, gradually integrating with the surrounding cartilage and bone tissue. This dual function of “immediate support, long-term repair” currently rests primarily on the product’s design and preclinical research and cannot yet be regarded as a regenerative effect demonstrated in patients.

The primary endpoint of this small study is not pain improvement or how much cartilage regrows, but the absence of serious device-related adverse effects within 12 months after implantation. The five-person sample size also means the study is better suited to identifying preliminary surgical and implantation risks and cannot draw reliable conclusions about efficacy, rare side effects, or the duration of any effects.

Nanochon’s first-in-human clinical program is not progressing only in Panama. Canada has approved another study expected to enroll 10 participants, and registration data show that study is recruiting. Panama’s authorization is therefore more accurately described as expanding the geographic reach and enrollment framework of this early human validation, rather than indicating that the product has obtained marketing authorization.

Chondrograft previously received Breakthrough Device designation from the U.S. FDA, which may allow closer regulatory communication during development, but this designation is not equivalent to approval of safety, efficacy, or marketing. The Panama trial’s registration status remains “not yet recruiting”; until implantations are actually completed and one-year follow-up data are obtained, whether the device can safely withstand loads in the knee joint and promote functional cartilage repair remains the central unanswered question.